Cencora, a global healthcare company, has expanded its Sure Supply Program to include 200 critical medications, including several oncology treatments, in response to ongoing drug shortages.

Feb 5 (Reuters) - Drug distributor Cencora (COR.N), opens new tab raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines. The Conshohocken ...

Last week, representatives from Cencora, formerly known as Amerisource Bergen, visited Keystone Health to gain insights into ...

Cencora’s Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the ...

We believe these services make the relationship between Cencora and its customers stickier. For customers, switching to a new distributor would mean loss ... essential to our mission of empowering ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

For the quarter ended December 2024, Cencora (COR) reported revenue of $81.49 billion, up 12.8% over the same period last year. EPS came in at $3.73, compared to $3.28 in the year-ago quarter.